0000000000348745
AUTHOR
Rafael Martínez-martínez
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
PETHEMA/GEM Cooperative Group.